Advertisement Jerini and PRP collaborate to develop formulations for eye diseases - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Jerini and PRP collaborate to develop formulations for eye diseases

Jerini and PR Pharmaceuticals have announced a license and development agreement between Jerini Ophthalmic, a wholly-owned and independently operated US subsidiary of Jerini, and PR Pharmaceuticals.

The new MAX technology provides tremendous power and performance optimization advantages for our customers’ products, regardless of the complexity of their designs, said Charlie Zhi, chief executive officer of Brite Semiconductor. Design companies in China are moving aggressively to leading-edge technologies. No other ASIC company will be able to offer these advanced design benefits to their China-based customers.

MAX has been tremendously successful in allowing customers to build the best possible, fully custom silicon for customers’ designs or products in smaller process geometries, said Scott Houghton, vice president of marketing and business development, Open-Silicon. Brite will be able to enhance its customers’ products by taking advantage of the ASIC industry’s only transistor-level optimization flow and techniques like adaptive back biasing, which are new to the ASIC space.